Scholarlink

<p>To compare perioperative and oncologic outcomes between single-port (SP) and multi-port (MP) retroperitoneal robotic-assisted partial nephrectomy (RAPN) in obese patients with renal tumors. A comprehensive literature search was conducted in PubMed, Embase, Scopus, and Web of Science up to July 2025. Eligible studies were those directly comparing SP-RAPN with MP-RAPN in obese patients (BMI ≥30&#xa0;kg/m<sup>2</sup>). Extracted data included operative duration, intraoperative blood loss, warm ischemia time, length of hospitalization, complication rates, and oncologic outcomes, which were synthesized using RevMan 5.4. Three retrospective studies involving 694 patients (252 SP, 442 MP) were included. SP-RAPN was associated with a shorter hospital stay (WMD = −0.29&#xa0;days, <i>P</i> = 0.02) but a longer warm ischemia time (WMD = 5.23&#xa0;min, <i>P</i> &lt; 0.00001). No significant differences were observed in operative time, estimated blood loss, complication rate, or positive surgical margins. The SP group had higher tumor complexity based on R.E.N.A.L. nephrometry scores. SP-RAPN demonstrates comparable safety and oncologic outcomes to MP-RAPN in obese patients, with the added benefit of reduced hospital stay. However, increased ischemia time should be considered when selecting the surgical approach. High-quality prospective trials are needed to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-port vs multi-port retroperitoneal robotic partial nephrectomy in obese patients: a meta-analysis of perioperative and functional outcomes

  • 期刊论文

  • 发表日期：

    2025年9月29日

查看全文
  • Kangyu Wang,
  • Changhong Xu,
  • Yun Deng,
  • Rui Yan,
  • Hao Wang,
  • Yalong Zhang,
  • Jiangwei Man,
  • Li Yang

摘要

To compare perioperative and oncologic outcomes between single-port (SP) and multi-port (MP) retroperitoneal robotic-assisted partial nephrectomy (RAPN) in obese patients with renal tumors. A comprehensive literature search was conducted in PubMed, Embase, Scopus, and Web of Science up to July 2025. Eligible studies were those directly comparing SP-RAPN with MP-RAPN in obese patients (BMI ≥30 kg/m2). Extracted data included operative duration, intraoperative blood loss, warm ischemia time, length of hospitalization, complication rates, and oncologic outcomes, which were synthesized using RevMan 5.4. Three retrospective studies involving 694 patients (252 SP, 442 MP) were included. SP-RAPN was associated with a shorter hospital stay (WMD = −0.29 days, P = 0.02) but a longer warm ischemia time (WMD = 5.23 min, P < 0.00001). No significant differences were observed in operative time, estimated blood loss, complication rate, or positive surgical margins. The SP group had higher tumor complexity based on R.E.N.A.L. nephrometry scores. SP-RAPN demonstrates comparable safety and oncologic outcomes to MP-RAPN in obese patients, with the added benefit of reduced hospital stay. However, increased ischemia time should be considered when selecting the surgical approach. High-quality prospective trials are needed to confirm these findings.